5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Daytime O
somnolence O
: O
Risk O
of O
impaired O
alertness O
and O
motor O
coordination O
, O
including O
impaired O
driving O
; O
risk O
increases O
with O
dose O
; O
caution O
patients O
taking O
20 O
mg O
against O
next-day O
driving O
and O
other O
activities O
requiring O
complete O
mental O
alertness O
( O
5.1 O
) O
. O

* O
Need O
to O
evaluate O
for O
co-morbid O
diagnoses O
: O
Reevaluate O
if O
insomnia O
persists O
after O
7 O
to O
10 O
days O
of O
treatment O
( O
5.2 O
) O
. O

* O
Nighttime O
`` O
sleep-driving O
'' O
and O
other O
complex O
behaviors O
while O
out O
of O
bed O
and O
not O
fully O
awake O
. O

Risk O
increases O
with O
dose O
, O
with O
use O
of O
CNS O
depressants O
, O
and O
with O
alcohol O
( O
5.3 O
) O
. O

* O
Depression O
: O
Worsening O
of O
depression O
or O
suicidal O
thinking O
may O
occur O
. O

Risk O
increases O
with O
dose O
. O

Immediately O
evaluate O
any O
new O
behavioral O
changes O
( O
5.4 O
) O
. O

* O
Compromised O
respiratory O
function O
: O
Effect O
on O
respiratory O
function O
should O
be O
considered O
( O
5.5 O
, O
8.6 O
) O
. O

* O
Sleep O
paralysis O
, O
hypnagogic/hypnopompic O
hallucinations O
, O
and O
cataplexy-like O
symptoms O
: O
Risk O
increases O
with O
dose O
( O
5.6 O
) O
. O

5.1 O
CNS O
Depressant O
Effects O
and O
Daytime O
Impairment O
BELSOMRA O
is O
a O
central O
nervous O
system O
( O
CNS O
) O
depressant O
that O
can O
impair B-OSE_Labeled_AE
daytime I-OSE_Labeled_AE
wakefulness I-OSE_Labeled_AE
even O
when O
used O
as O
prescribed O
. O

Prescribers O
should O
monitor O
for O
somnolence B-NonOSE_AE
and O
CNS B-NonOSE_AE
depressant I-NonOSE_AE
effects I-NonOSE_AE
, O
but O
impairment O
can O
occur O
in O
the O
absence O
of O
symptoms O
, O
and O
may O
not O
be O
reliably O
detected O
by O
ordinary O
clinical O
exam O
( O
i.e. O
, O
less O
than O
formal O
testing O
of O
daytime O
wakefulness O
and/or O
psychomotor O
performance O
) O
. O

CNS B-OSE_Labeled_AE
depressant I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
may O
persist O
in O
some O
patients O
for O
up O
to O
several O
days O
after O
discontinuing O
BELSOMRA O
. O

BELSOMRA O
can O
impair B-OSE_Labeled_AE
driving I-OSE_Labeled_AE
skills I-OSE_Labeled_AE
and O
may O
increase B-OSE_Labeled_AE
the I-OSE_Labeled_AE
risk I-OSE_Labeled_AE
of I-OSE_Labeled_AE
falling I-OSE_Labeled_AE
asleep I-OSE_Labeled_AE
while I-OSE_Labeled_AE
driving I-OSE_Labeled_AE
. O

Discontinue O
or O
decrease O
the O
dose O
in O
patients O
who O
drive O
if O
daytime B-NonOSE_AE
somnolence I-NonOSE_AE
develops O
. O

In O
a O
study O
of O
healthy O
adults O
, O
driving B-OSE_Labeled_AE
ability I-OSE_Labeled_AE
was I-OSE_Labeled_AE
impaired I-OSE_Labeled_AE
in O
some O
individuals O
taking O
20 O
mg O
BELSOMRA O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
. O

Although O
pharmacodynamic O
tolerance O
or O
adaptation O
to O
some O
adverse O
depressant O
effects O
of O
BELSOMRA O
may O
develop O
with O
daily O
use O
, O
patients O
using O
the O
20 O
mg O
dose O
of O
BELSOMRA O
should O
be O
cautioned O
against O
next-day O
driving O
and O
other O
activities O
requiring O
full O
mental O
alertness O
. O

Patients O
taking O
lower O
doses O
of O
BELSOMRA O
should O
also O
be O
cautioned O
about O
the O
potential O
for O
driving B-NonOSE_AE
impairment I-NonOSE_AE
because O
there O
is O
individual O
variation O
in O
sensitivity O
to O
BELSOMRA O
. O

Co-administration O
with O
other O
CNS O
depressants O
( O
e.g. O
, O
benzodiazepines O
, O
opioids O
, O
tricyclic O
antidepressants O
, O
alcohol O
) O
increases B-NonOSE_AE
the I-NonOSE_AE
risk I-NonOSE_AE
of I-NonOSE_AE
CNS I-NonOSE_AE
depression I-NonOSE_AE
. O

Patients O
should O
be O
advised O
not O
to O
consume O
alcohol O
in O
combination O
with O
BELSOMRA O
because O
of O
additive O
effects O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Dosage O
adjustments O
of O
BELSOMRA O
and O
of O
concomitant O
CNS O
depressants O
may O
be O
necessary O
when O
administered O
together O
because O
of O
potentially O
additive O
effects O
. O

The O
use O
of O
BELSOMRA O
with O
other O
drugs O
to O
treat O
insomnia B-Not_AE_Candidate
is O
not O
recommended O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

The O
risk O
of O
next B-NonOSE_AE
- I-NonOSE_AE
day I-NonOSE_AE
impairment I-NonOSE_AE
, O
including O
impaired B-NonOSE_AE
driving I-NonOSE_AE
, O
is O
increased O
if O
BELSOMRA O
is O
taken O
with O
less O
than O
a O
full O
night O
of O
sleep O
remaining O
, O
if O
a O
higher O
than O
the O
recommended O
dose O
is O
taken O
, O
if O
co-administered O
with O
other O
CNS O
depressants O
, O
or O
if O
co-administered O
with O
other O
drugs O
that O
increase O
blood O
levels O
of O
BELSOMRA O
. O

Patients O
should O
be O
cautioned O
against O
driving O
and O
other O
activities O
requiring O
complete O
mental O
alertness O
if O
BELSOMRA O
is O
taken O
in O
these O
circumstances O
. O

5.2 O
Need O
to O
Evaluate O
for O
Co-morbid O
Diagnoses O
Because O
sleep B-Not_AE_Candidate
disturbances I-Not_AE_Candidate
may O
be O
the O
presenting O
manifestation O
of O
a O
physical B-Not_AE_Candidate
and/or O
psychiatric O
disorder I-Not_AE_Candidate
, O
treatment O
of O
insomnia B-Not_AE_Candidate
should O
be O
initiated O
only O
after O
careful O
evaluation O
of O
the O
patient O
. O

The O
failure O
of O
insomnia B-Not_AE_Candidate
to O
remit O
after O
7 O
to O
10 O
days O
of O
treatment O
may O
indicate O
the O
presence O
of O
a O
primary O
psychiatric B-Not_AE_Candidate
and/or O
medical O
illness I-Not_AE_Candidate
that O
should O
be O
evaluated O
. O

Worsening B-Not_AE_Candidate
of I-Not_AE_Candidate
insomnia I-Not_AE_Candidate
or O
the O
emergence O
of O
new O
cognitive B-Not_AE_Candidate
or O
behavioral O
abnormalities I-Not_AE_Candidate
may O
be O
the O
result O
of O
an O
unrecognized O
underlying O
psychiatric B-Not_AE_Candidate
or O
physical O
disorder I-Not_AE_Candidate
, O
and O
can O
emerge O
during O
the O
course O
of O
treatment O
with O
hypnotic O
drugs O
such O
as O
BELSOMRA O
. O

5.3 O
Abnormal O
Thinking O
and O
Behavioral O
Changes O
A O
variety O
of O
cognitive B-OSE_Labeled_AE
and O
behavioral O
changes I-OSE_Labeled_AE
( O
e.g. O
, O
amnesia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
and O
other O
neuro B-OSE_Labeled_AE
- I-OSE_Labeled_AE
psychiatric I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
) O
have O
been O
reported O
to O
occur O
in O
association O
with O
the O
use O
of O
hypnotics O
such O
as O
BELSOMRA O
. O

Complex B-OSE_Labeled_AE
behaviors I-OSE_Labeled_AE
such O
as O
" B-OSE_Labeled_AE
sleep I-OSE_Labeled_AE
- I-OSE_Labeled_AE
driving I-OSE_Labeled_AE
" I-OSE_Labeled_AE
( O
i.e. O
, O
driving B-OSE_Labeled_AE
while I-OSE_Labeled_AE
not I-OSE_Labeled_AE
fully I-OSE_Labeled_AE
awake I-OSE_Labeled_AE
after O
taking O
a O
hypnotic O
) O
and O
other O
complex B-OSE_Labeled_AE
behaviors I-OSE_Labeled_AE
( O
e.g. O
, O
preparing B-OSE_Labeled_AE
and I-OSE_Labeled_AE
eating I-OSE_Labeled_AE
food I-OSE_Labeled_AE
, O
making O
phone O
calls O
, O
or O
having O
sex O
) O
, O
with I-OSE_Labeled_AE
amnesia I-OSE_Labeled_AE
for I-OSE_Labeled_AE
the I-OSE_Labeled_AE
event I-OSE_Labeled_AE
, O
have O
been O
reported O
in O
association O
with O
the O
use O
of O
hypnotics O
. O

These O
events O
can O
occur O
in O
hypnotic-naive O
as O
well O
as O
in O
hypnotic-experienced O
persons O
. O

The O
use O
of O
alcohol O
and O
other O
CNS O
depressants O
may O
increase O
the O
risk O
of O
such O
behaviors O
. O

Discontinuation O
of O
BELSOMRA O
should O
be O
strongly O
considered O
for O
patients O
who O
report O
any O
complex B-NonOSE_AE
sleep I-NonOSE_AE
behavior I-NonOSE_AE
. O

5.4 O
Worsening O
of O
Depression/Suicidal O
Ideation O
In O
clinical O
studies O
, O
a O
dose-dependent O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
suicidal I-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
was O
observed O
in O
patients O
taking O
BELSOMRA O
as O
assessed O
by O
questionnaire O
. O

Immediately O
evaluate O
patients O
with O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
or O
any O
new O
behavioral O
sign O
or O
symptom O
. O

In O
primarily O
depressed B-Not_AE_Candidate
patients O
treated O
with O
sedative-hypnotics O
, O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
and O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
and O
actions O
( O
including O
completed B-OSE_Labeled_AE
suicides I-OSE_Labeled_AE
) O
have O
been O
reported O
. O

Suicidal B-NonOSE_AE
tendencies I-NonOSE_AE
may O
be O
present O
in O
such O
patients O
and O
protective O
measures O
may O
be O
required O
. O

Intentional B-NonOSE_AE
overdose I-NonOSE_AE
is O
more O
common O
in O
this O
group O
of O
patients O
; O
therefore O
, O
the O
lowest O
number O
of O
tablets O
that O
is O
feasible O
should O
be O
prescribed O
for O
the O
patient O
at O
any O
one O
time O
. O

The O
emergence O
of O
any O
new O
behavioral B-NonOSE_AE
sign I-NonOSE_AE
or I-NonOSE_AE
symptom I-NonOSE_AE
of O
concern O
requires O
careful O
and O
immediate O
evaluation O
. O

5.5 O
Patients O
with O
Compromised O
Respiratory O
Function O
Effect O
of O
BELSOMRA O
on O
respiratory O
function O
should O
be O
considered O
if O
prescribed O
to O
patients O
with O
compromised B-Not_AE_Candidate
respiratory I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

BELSOMRA O
has O
not O
been O
studied O
in O
patients O
with O
severe O
obstructive B-Not_AE_Candidate
sleep I-Not_AE_Candidate
apnea I-Not_AE_Candidate
( O
OSA O
) O
or O
severe O
chronic B-Not_AE_Candidate
obstructive I-Not_AE_Candidate
pulmonary I-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
COPD O
) O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

5.6 O
Sleep O
Paralysis O
, O
Hypnagogic/Hypnopompic O
Hallucinations O
, O
Cataplexy-like O
Symptoms O
Sleep B-OSE_Labeled_AE
paralysis I-OSE_Labeled_AE
, O
an O
inability B-NonOSE_AE
to I-NonOSE_AE
move I-NonOSE_AE
or I-NonOSE_AE
speak I-NonOSE_AE
for I-NonOSE_AE
up I-NonOSE_AE
to I-NonOSE_AE
several I-NonOSE_AE
minutes I-NonOSE_AE
during I-NonOSE_AE
sleep I-NonOSE_AE
- I-NonOSE_AE
wake I-NonOSE_AE
transitions I-NonOSE_AE
, O
and O
hypnagogic B-OSE_Labeled_AE
/hypnopompic O
hallucinations I-OSE_Labeled_AE
, O
including O
vivid B-NonOSE_AE
and O
disturbing O
perceptions I-NonOSE_AE
by O
the O
patient O
, O
can O
occur O
with O
the O
use O
of O
BELSOMRA O
. O

Prescribers O
should O
explain O
the O
nature O
of O
these O
events O
to O
patients O
when O
prescribing O
BELSOMRA O
. O

Symptoms B-OSE_Labeled_AE
similar I-OSE_Labeled_AE
to I-OSE_Labeled_AE
mild I-OSE_Labeled_AE
cataplexy I-OSE_Labeled_AE
can O
occur O
, O
with O
risk O
increasing O
with O
the O
dose O
of O
BELSOMRA O
. O

Such O
symptoms O
can O
include O
periods O
of O
leg B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
lasting O
from O
seconds O
to O
a O
few O
minutes O
, O
can O
occur O
both O
at O
night O
and O
during O
the O
day O
, O
and O
may O
not O
be O
associated O
with O
an O
identified O
triggering O
event O
( O
e.g. O
, O
laughter O
or O
surprise O
) O
. O

